Insulins(Halozyme)

Autonomous labs are transforming scientific research, using AI and automation to accelerate experimentation and discovery. Credit: Waters Corporation This week's top stories include Danaher and NVIDIA's autonomous AI partnership, Rush and Endeavor's merger, FedEx's pharma logistics portal and more 1. Danaher and NVIDIA Partner to Accelerate Autonomous Science Danaher is stepping up efforts to influence the future of AI-enabled science. Just days after announcing plans to launch its “ first AI-powered autonomous lab ”, the diagnostics giant announced a partnership with the world’s most valuable company and AI technology innovator, NVIDIA , to “advance autonomous science.” The collaboration combines Danaher’s scientific instruments, automation technologies, laboratory workflow software and life sciences expertise with NVIDIA’s accelerated computing and AI capabilities. By integrating these technologies, the companies aim to help researchers move more quickly from computational predictions to experimental validation, creating a continuous feedback loop in which experimental results refine AI models and those models inform the design of future experiments. “By combining Danaher's workflows, data and deep scientific expertise with NVIDIA's AI and accelerated computing capabilities, we're creating a faster, more connected research process,” writes Danaher CEO Julie Sawyer Montgomery on LinkedIn. “The goal is a continuous cycle where experiments improve AI models, and those models help scientists design better experiments. “And that's what gets me excited. Helping researchers move faster to advance discoveries that can improve patients' lives.” 2. Rush and Endeavor Plan Merger to Expand Care and Research The Rush-Endeavor combined organisation will employ more than 46,000 team members and clinicians. Credit: Rush University. Credit: Rush Rush University System for Health and Endeavor Health have announced plans to merge, bringing together two major healthcare providers serving Chicago and the wider Illinois region to create an integrated academic health system spanning 12 hospitals and more than 400 care sites. The combined organisation will operate under the Rush brand and employ more than 46,000 team members and clinicians, serving more than 2 million patients annually across northern Illinois and Northwest Indiana. The proposed merger aims to combine Rush's academic, research and clinical expertise with Endeavor's extensive regional care network, creating opportunities to expand access to high-quality care, accelerate medical innovation and strengthen relationships with the communities both organisations serve. Gerald “J.P.” Gallagher, President and CEO of Endeavor Health, will lead the unified system as President and CEO once the transaction closes. Dr Omar Lateef, President and CEO of Rush University System for Health and Rush University Medical Centre, will remain in his current position until completion, before becoming CEO Emeritus and Strategic Advisor to the CEO. Governance will be overseen by a 20-member system Board, with equal representation from Rush and Endeavor Health and a chair drawn from the Rush system. Writing on LinkedIn following the announcement, J.P. says: “Together we will advance our shared mission as an integrated academic health system deeply connected to the communities we serve across greater Chicagoland.” 3. FedEx Europe Launches Portal to Improve Pharma Logistics FedEx Europe has launched a new online portal that enables pharmaceutical and life sciences companies to book and manage temperature-controlled shipments. Credit: FedEx The end-of-year peak season brings a surge in pharmaceutical shipping activity across Europe, with volumes for major logistics companies such as FedEx sometimes reaching a peak of two million packages a day. Preparing for this increase in demand, while maintaining the integrity of temperature-sensitive , patient-critical medicines, places additional strain on pharmaceutical supply chains. To help customers prepare for these challenges, FedEx Europe has launched a digital portal enabling pharmaceutical and life sciences companies to book and manage temperature-controlled shipments. Available across 26 European markets, the platform provides access to FedEx's Temp-Assure Advantage solution. Customers can onboard, order pre-conditioned packaging, schedule shipments and manage returns through a streamlined digital experience, helping them coordinate critical deliveries more efficiently. “The portal helps provide greater visibility and control throughout the shipping process, supporting more efficient planning and execution,” says Toby Hay, Managing Director of International Marketing at FedEx Europe. “While it does not simplify the complexity of healthcare logistics itself, it helps customers manage shipments more effectively, maintain operational continuity and respond more quickly to changing business needs.” 4. Waters: Integrating Anthropic AI Into Laboratory Workflows Global life sciences and diagnostics leader Waters Corporation is aiming to connect AI directly to its laboratory instruments, enabling pharmaceutical researchers to move from AI-generated hypotheses to physical experiments with less manual intervention. Central to this goal is the company's launch of Waters AI Link, a software capability that brings Anthropic ’s Model Context Protocol (MCP) to its waters_connect informatics platform. The integration allows scientists to use natural language to direct Waters instruments and manage laboratory workflows through AI models and agents, including Anthropic’s Claude and Claude Science . AI Link supports tasks such as creating methods, running acquisitions and processing results, while coordinating connected equipment such as sample preparation systems. Waters’ announcement is the latest example of a wider industry shift, as automated, AI-powered research environments increasingly blur the lines between computational research and physical experimentation. 5. Sanofi Invests in Europe’s Pharma Manufacturing Future Representatives from Sanofi and regional German politics attended the opening ceremony at Sanofi's Frankfurt BioCampus. Credit: Belén Garijo via LinkedIn French pharmaceutical giant Sanofi has demonstrated its continued commitment to European pharmaceutical manufacturing amid fears that the continent is struggling to compete with rival markets . The company has broken ground on a new insulin manufacturing facility at its BioCampus in Frankfurt, Germany, in a major investment aimed at strengthening its production capabilities and supply chain resilience. According to Sanofi, the facility will “bring a new generation of insulin production” to one of the company’s largest integrated research and manufacturing sites, helping meet the needs of millions of people living with diabetes worldwide. Brendan O’Callaghan, Head of Manufacturing and Supply at Sanofi, says the investment builds on the company’s longstanding expertise in insulin production while bringing new technologies to the site. “With this investment, we are building on more than 100 years of experience in insulin manufacturing at the site, to bring the latest innovations in Biopharma manufacturing to help us further advance the supply of Insulins for the increasing number of patients living with Diabetes, in Europe and around the world,” he writes on LinkedIn. Company portals Anthropic Danaher Endeavor Health FedEx NVIDIA Rush University Medical Center Sanofi Waters Executives Brendan O'Callaghan Executive Vice President, Manufacturing and Supply J.P. Gallagher President & CEO, Endeavor Health Julie Sawyer Montgomery CEO Toby Hay Managing Director of International Marketing

Updated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic excursions DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Prescribing Information for Afrezza® (insulin human) Inhalation Powder, revising recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. “We expect that this label update will help support healthcare providers by providing clearer starting dose guidance when transitioning patients to inhaled insulin from subcutaneous mealtime insulin—whether injections or insulin pumps,” said Dr. Kevin Kaiserman, Senior Vice President, Therapeutic Area Head, Diabetes at MannKind Corporation. “We believe this refinement to the label helps support appropriate initiation of therapy while reinforcing Afrezza’s established clinical profile.” The updated labeling was supported by modeling data and in vivo results from the Dose Optimization study (see graph) and the INHALE-3 trial that demonstrated improved postprandial glucose outcomes following conversion to inhaled insulin using the now-approved conversion dose. The revised dosing recommendations, provided in the table below, include recommended dose conversions from injected mealtime insulin or insulin pump bolus dosing to the appropriate mealtime dosage of Afrezza and are intended to support a clinically appropriate and safe transition for adult patients initiating Afrezza. Please see the Full Prescribing Information for additional details. Table 1: Recommended Starting Mealtime Dosage of Afrezza when Switching from Other Mealtime Insulin Regimens Current Subcutaneous Mealtime Insulin DosageStarting Dosage of AFREZZAUp to 3 units4 units4 to 5 units8 units6 to 7 units12 units8 or more units16 units About AfrezzaAfrezza® (pronounced uh-frezz-uh) Inhalation Powder is the only ultra rapid-acting inhaled insulin approved by the U.S. Food and Drug Administration to improve glycemic control in adult patients with diabetes mellitus. Administered at the beginning of meals using a small, portable inhaler, Afrezza delivers insulin via MannKind’s proprietary Technosphere® technology, enabling ultra-rapid absorption through the lungs. Afrezza has a fast onset of action and a short duration, more closely mirroring the body’s natural insulin response to meals. INDICATION AND IMPORTANT SAFETY INFORMATION WITH WARNINGS Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis or in patients that smoke or have recently stopped smoking. WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE Acute bronchospasm has been observed in Afrezza-treated patients with asthma and chronic obstructive pulmonary disease (COPD)Afrezza is contraindicated in patients with chronic lung disease such as asthma or COPDBefore initiating Afrezza, perform a detailed medical history, physical examination, and spirometry (FEV1) to identify potential lung disease in all patients. Afrezza is contraindicated: during episodes of hypoglycemia, in patients with chronic lung disease (such as asthma or COPD) because of the risk of acute bronchospasm, and in patients with previous severe hypersensitivity reaction to regular human insulin product or any of the inactive ingredients in Afrezza. Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with Afrezza. In a study of patients with asthma whose bronchodilators were temporarily withheld for assessment, bronchoconstriction and wheezing following Afrezza dosing was reported. Before initiating therapy, evaluate all patients with a medical history, physical examination, and spirometry (FEV1) to identify potential underlying lung disease. Do not use in patients with chronic lung disease such as asthma or COPD. Changes in an insulin regimen (e.g., insulin strength, manufacturer, injection site or type, or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. If clinically indicated, make any necessary changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. For patients with type 2 diabetes, dosage modifications of concomitant oral antidiabetic treatment may be needed. Hypoglycemia is the most common adverse reaction associated with insulins, including Afrezza. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Hypoglycemia can happen suddenly, and symptoms may differ across patients and change over time in the same patient. Advise patients to recognize and manage hypoglycemia and self-monitor glucose. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of glucose monitoring is recommended. Afrezza causes a decline in lung pulmonary function over time as measured by FEV1. In clinical trials excluding patients with chronic lung disease and lasting up to 2 years, Afrezza-treated patients experienced a small (40 mL) but greater FEV1 decline than comparator-treated patients. Assess pulmonary function with spirometry at baseline, after the first 6 months of therapy and annually thereafter even in the absence of pulmonary symptoms. In patients who have a decline of ≥20% in FEV1 from baseline, consider discontinuing Afrezza. Consider more frequent lung function assessment in patients with pulmonary symptoms, e.g., wheezing, bronchospasm, breathing difficulties, or persistent or recurring cough. If symptoms persist, discontinue Afrezza. In clinical trials, 2 cases of lung cancer were observed in patients exposed to Afrezza while no cases were reported for the comparators. In both cases, a prior history of heavy tobacco use was identified as a risk factor for lung cancer. Two additional cases of lung cancer (squamous cell and lung blastoma) were reported in non-smokers exposed to Afrezza after the trial completion. These data are insufficient to determine whether Afrezza has an effect on lung or respiratory tract tumors. In patients with active lung cancer, a prior history of lung cancer, or in patients at risk of lung cancer, consider whether the benefits of Afrezza use outweigh this potential risk. In clinical trials enrolling patients with type 1 diabetes, diabetic ketoacidosis (DKA) was more common in Afrezza-treated patients (0.43%; n=13) than in comparator-treated patients (0.14%; n=3). Patients with type 1 diabetes should always use Afrezza concomitantly with basal insulin. In patients at risk for DKA, such as those with an acute illness or infection, increase the frequency of glucose monitoring and consider discontinuing Afrezza and giving insulin using an alternate route of administration. Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products. If hypersensitivity reactions occur, discontinue Afrezza, treat per standard of care and monitor until symptoms and signs resolve. All insulin products, including Afrezza, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated. Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. Observe these patients for signs and symptoms of heart failure. If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the TZD should be considered. Most common adverse reactions are hypoglycemia, cough, and throat pain or irritation. Please see additional Important Safety Information, Full Prescribing Information, including BOXED WARNING, available on Afrezza.com/safety. About MannKindMannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life. Learn more at mannkindcorp.com. Forward-Looking StatementsStatements in this press release that are not statements of historical fact are forward-looking statements that involve risks and uncertainties. These statements include, without limitation, statements regarding clearer guidance regarding the initiation of insulin therapy. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with developing and commercializing product candidates and other risks detailed in MannKind’s filings with the Securities and Exchange Commission (“SEC”), including under the “Risk Factors” heading of its most recently filed Quarterly Report on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release. AFREZZA, MANNKIND and TECHNOSPHERE are registered trademarks of MannKind Corporation. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9c8efef3-3fac-4191-b791-45429abb7399 MannKind Contacts: Media Relations: Christie Iacangelo (818) 292-3500 media@mnkd.com Investor Relations: Kate Miranda (781) 301-6869 ir@mnkd.com